Physician profile
Mohammed Asif
NPI 1811928674
$784.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $220 · 2022: $71.98 · 2023: $170 · 2024: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.61 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $148.53 | 2019-2024 | Breztri |
| Lilly USA, LLC | $147.40 | 2020-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $84.22 | 2020-2024 | Shingrix |
| Amgen INC. | $55.68 | 2023-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $39.28 | 2020 | |
| Pfizer INC. | $38.59 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $23.13 | 2019 | |
| Exact Sciences Corporation | $19.29 | 2023 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $18.06 | 2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $16.48 | 2020 | |
| Allergan, INC. | $13.39 | 2020 | |
| Merck Sharp & Dohme LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Asif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.